Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


BioXell Appoints Professor Peter van Brummelen to its Board of Directors

Professor Peter van Brummelen is currently an independent consultant to the pharmaceutical industry. As Executive Vice President of Research and Development at Yamanouchi Europe, from 1998 to 2003, he was responsible for the rapid and successful development of the new muscarinic antagonist, solifenacin, in overactive bladder as well as for the development of a new formulation of tamsulosin in benign prostatic hyperplasia. His previous positions include Vice President of Clinical Operations at Solvay Pharmaceuticals, Global Head of Clinical Pharmacology at Hoffmann-La Roche in Basel, and Professor of Medicine at the Universities of Leiden and Basel. Professor van Brummelen also serves as a Director on the Board of Basilea Pharmaceutica in Switzerland and of IQ Corporation in The Netherlands.

Professor van Brummelen stated: 'I am delighted to join the Board of Bioxell, a company recognised for its strong technology platform and promising development candidates”.

Francesco Sinigaglia, Chief Executive Officer of BioXell commented: “The addition of Peter reinforces the world-class leadership, in terms of both breadth and depth of experience, already evident in our Board. With the significant progress of 2004 behind us, we are now in a strong position to advance our lead compound, BXL628, in two Phase II trials, in two additional indications. The completion of a €23m financing in the fourth quarter of 2004 provides a strong cash position and underscores our ability to not only maintain, but also create new clinical momentum with BXL628”.

About BioXell
Spun-out from Roche in January 2002, BioXell is a private biopharmaceutical company focusing on the discovery and development of new treatments for urological disorders that represent large, currently underserved markets. Through its proprietary technology platform based on Vitamin D3 analogues, BioXell has identified a number of promising lead development programmes. Its pipeline includes BXL628 for benign prostatic hyperplasia and overactive bladder, currently in Phase II of clinical development, as well as compounds to treat other major urological indications such as interstitial cystitis and nonbacterial chronic prostatitis. In order to further exploit its Vitamin D3 platform, BioXell is collaborating with ProStrakan to develop drug candidates to cure osteoporosis and secondary hyperparathyroidism. Furthermore, based on its unique understanding of the inflammatory process and knowledge of GPCRs and TREM receptor biology, BioXell is also committed to a number of cutting-edge research projects to develop new drugs for chronic inflammatory diseases in collaboration with external partners. To date, BioXell has raised a total of over €70m through world-class specialised healthcare VC investors including MPM Capital, Index Ventures, AlpInvest Partners, BB BIOTECH and Life Science Partners as well as government funding. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA.

More information on BioXell can be found on:


BioXell SpA
Alvise Sagramoso/Angela Evans
BioXell S.p.A
Via Olgettina 58
Tel: +39 (0)2 210 49 520
Fax: +39 (0)2 210 49 555

Financial Dynamics
Julia Phillips/Davina Langdale

Financial Dynamics
Holborn Gate
26 Southampton Buildings
London WC2A 1PB
United Kingdom
Tel: +44 (0)20 7269 7187
Fax: +44 (0)20 7242 8695

Publisher Contact Information:

Bioxell S.p.A.
+39 02-2104951

Company profile of Bioxell S.p.A.
Past press releases of Bioxell S.p.A..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jun 28€15.0MBroadcast
Jun 18€53.0MInternet services
Jun 18€3.0MInternet services
Jun 18€5.7MSecurity
Jun 17€4.5MArtificial Intelligence
Jun 17€24.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.